Overview

IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)

Status:
Recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)

Phase:

Phase 3

Details

Lead Sponsor:

CymaBay Therapeutics, Inc.

Treatments:

Seladelpar